We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience.

This review indicates an association between psychedelic therapy and significant reduction of depressive symptoms at several time points.

COMPASS’ program will be the first ever Phase 3 program of psilocybin therapy.

Ecstasy use was also associated with significantly higher odds of better self-reported overall health.

On the overall harm scale, N2O scored 6, just above magic mushrooms (psilocybin) while ‘poppers’ scored 5. Together these are the three lowest drugs on the overall harm scale.

The question on everybody’s lips was – ‘how can we implement psychedelics into our pre-existing healthcare systems safely, legally, and responsibly?’.

Psychedelic therapy is perhaps the most exciting new development in psychiatry.

The focus of this review is on answering specific questions about the effects of psychedelics on neuroplasticity.

Participant narratives also showed a reconnection to life and greater emotional resilience in response to trauma and medical relapse.

There appears to be a recent uptrend in registered clinical trials studying psychedelics, which is similar to the recent increase in overall trials registered.

A growing body of evidence shows that psilocybin is safe and can relieve symptoms of depression and end-of-life demoralization in people with cancer and other life-threatening conditions.

Given the potential of psychedelic compounds to benefit older adults, more research is needed to establish safety and efficacy among older adults

This study was designed to review the brief history of the novel antidepressant arketamine, the molecular mechanisms underlying its antidepressant actions, and future directions.

Heavy drinking days decreased by about 80% among those in the psilocybin group.